Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Carcinoma, Non-Small-Cell Lung 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Multiple Myeloma 5Breast Neoplasms 5Wilms Tumor 4Prostatic Neoplasms 4Neoplasms 4Hematologic Neoplasms 4Burkitt Lymphoma 4Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 3Plasmablastic Lymphoma 3Pancreatic Neoplasms 3Lymphoma, Mantle-Cell 3Lymphoma 3HIV Infections 3Ependymoma 3Colorectal Neoplasms 3Astrocytoma 3Recurrence 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Melanoma 2Medulloblastoma 2Lymphoma, T-Cell 2Lymphoma, Non-Hodgkin 2Lymphoma, Follicular 2Lung Neoplasms 2Leukemia, Myeloid, Acute 2Kidney Neoplasms 2Hodgkin Disease 2Head and Neck Neoplasms 2

Interventions

dexamethasone acetate 1dexamethasone 21-phosphate 1daratumumab 1auricularum 1Lenalidomide 1Dexamethasone 1Calcium Dobesilate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Smoldering Multiple Myeloma × 30 days × Clear all
NCT03937635 2026-05-15

Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

Eastern Cooperative Oncology Group

Phase 3 Recruiting
288 enrolled
Plasma cell

Smoldering Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡